TScan Therapeutics (TCRX) AI Stock Analysis

• Market Cap: $98.74M
• Dividend Yield: N/A
• Average Volume (3M): 231.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: -42.94%
• EPS Growth: N/A
• Country: US
• Employees: 200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 52,471,405
• 10 Day Avg. Volume: 264,677
• 30 Day Avg. Volume: 231,969
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 9.59
• Enterprise Value/Gross Profit: 10.68
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: $8.60
• Price Target Upside: 394.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-13.79% Downside)

The overall stock score of 46 reflects significant challenges in financial performance, particularly in profitability and cash flow. Technical analysis shows mixed signals with some medium-term support, but short-term weakness. Valuation is impacted by negative earnings, and the absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and successful product development, crucial for long-term sustainability in the biotech sector.

Cash Flow Improvement

Improving cash flow generation enhances financial flexibility, allowing TScan to invest in R&D and strategic initiatives, supporting long-term growth.

High Gross Profit Margin

Efficient cost management reflected in high gross margins allows TScan to reinvest in innovation and maintain competitive advantages in the biotech industry.

Negative Factors

Negative Profitability

Persistent negative profitability metrics indicate operational challenges, potentially limiting TScan's ability to self-fund growth and innovation.

Negative Return on Equity

A negative return on equity suggests inefficiencies in generating shareholder returns, which could deter investment and affect long-term capital raising.

Cash Flow Challenges

Significant cash flow challenges may hinder TScan's ability to sustain operations without external financing, impacting long-term financial health.

TScan Therapeutics Business Overview & Revenue Model

Company Description

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

TScan Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potentially through future sales of its therapeutic products once they receive regulatory approval. The company may enter into strategic partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the products developed from these collaborations. Additionally, TScan may receive funding through grants and other financial support aimed at advancing its research initiatives.

TScan Therapeutics Financial Statement Overview

Summary

TScan Therapeutics shows strong revenue growth but faces significant profitability challenges with negative margins. The balance sheet indicates moderate leverage and a solid equity base, yet the negative return on equity is concerning. Cash flow improvements are noted, but the company still faces cash flow difficulties.

Income Statement

TScan Therapeutics shows a significant revenue growth rate of 57.45% in the TTM, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The high gross profit margin of 81.70% in the TTM suggests efficient cost management, but the overall negative margins highlight ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio of 0.36 in the TTM indicates a moderate level of leverage, which is manageable. However, the negative return on equity of -63.84% suggests that the company is not generating sufficient returns for its shareholders. The equity ratio of 59.19% reflects a solid capital structure, but the overall financial health is weakened by the negative profitability metrics.

Cash Flow

TScan Therapeutics has a positive free cash flow growth rate of 6.03% in the TTM, showing some improvement in cash generation. However, the operating cash flow to net income ratio of -4.03 indicates significant cash flow challenges. The free cash flow to net income ratio of 1.04 suggests that the company is generating slightly more free cash flow than net income, but the overall cash flow situation remains strained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.96M	2.82M	21.05M	13.54M	10.14M	1.08M
Gross Profit	6.25M	2.82M	-67.10M	8.40M	6.81M	-19.49M
EBITDA	-130.55M	-119.74M	-80.10M	-59.91M	-45.30M	-25.00M
Net Income	-136.78M	-127.50M	-89.22M	-65.81M	-48.63M	-26.02M
Balance Sheet
Total Assets	298.56M	371.12M	272.15M	199.09M	188.11M	49.74M
Cash, Cash Equivalents and Short-Term Investments	218.04M	290.11M	192.04M	120.03M	161.41M	34.79M
Total Debt	64.40M	97.38M	92.43M	85.98M	6.04M	7.43M
Total Liabilities	121.85M	130.15M	121.28M	99.66M	27.33M	92.20M
Stockholders Equity	176.71M	240.97M	150.87M	99.43M	160.78M	-42.46M
Cash Flow
Free Cash Flow	-131.25M	-114.65M	-64.50M	-70.73M	-58.62M	-7.26M
Operating Cash Flow	-126.18M	-110.82M	-61.36M	-66.50M	-48.68M	-3.02M
Investing Cash Flow	6.91M	-52.61M	-60.76M	-4.22M	-9.94M	-4.24M
Financing Cash Flow	46.51M	208.76M	135.44M	29.36M	189.67M	288.00K

TScan Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 1.74 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 1.79, and below the 200-day MA of 1.88, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 69.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.

TScan Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVM	49 Neutral	$94.64M	-0.57	-185.15%	―	―	1.80%
TCRX	46 Neutral	$98.74M	―	-63.33%	―	-42.94%	―
ADAG	45 Neutral	$92.38M	-3.05	-66.16%	―	-87.65%	11.76%
CNTX	37 Underperform	$81.63M	-2.30	―	―	―	62.83%
RANI	32 Underperform	$34.50M	-0.53	―	―	―	22.94%
ELTX	30 Underperform	$179.72M	-2.63	―	―	―	-4.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

TScan Therapeutics Corporate Events

TScan Therapeutics Updates Corporate Milestones and Strategies

On September 9, 2025, TScan Therapeutics released an updated corporate presentation outlining revised development and operational milestones, including adjusted timelines for its solid tumor program and updates on its pipeline for hematologic malignancies. The presentation, intended for investors and stakeholders, reflects the company’s ongoing efforts in target discovery initiatives in autoimmunity and highlights its strategic focus on advancing its TCR-T therapy candidates. This update is significant for stakeholders as it provides insights into TScan’s future growth strategies and its potential impact on the biotechnology industry.

The most recent analyst rating on (TCRX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.